Clinical Trials Browser

Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Blood Component Removal × Clear all

NCT07166419 2025-12-24

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00499889 2012-04-23

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

Phase 2 Terminated

42 enrolled 8 charts

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive